Login / Signup

Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal Impairment.

Hengli ZhaoZhirui ZhaoKun HeNianrong MiKai LouXiaolin DongWenyu ZhangJingfang SunXinyu HuShuguang PangHong ChengQing Wen
Published in: Clinical pharmacokinetics (2023)
China Drug Trial register ( http://www.chinadrugtrials.org.cn/I ) identifier no.: CTR20192721.
Keyphrases
  • study protocol
  • phase iii
  • phase ii
  • lymph node metastasis
  • clinical trial
  • glycemic control
  • adverse drug
  • cardiovascular risk factors
  • drug induced
  • squamous cell carcinoma
  • type diabetes
  • open label
  • weight loss